NCT03104699: Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer

NCT03104699
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for dose escalation phase
Exclusions: 
https://ClinicalTrials.gov/show/NCT03104699

Comments are closed.

Up ↑